Corvus Pharmaceuticals (CRVS) Liabilities and Shareholders Equity (2015 - 2026)

Corvus Pharmaceuticals' Liabilities and Shareholders Equity history runs 12 years deep, the most recent figure standing at $253.2 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 325.98% year-over-year to $253.2 million in Q1 2026; TTM through Mar 2026 was $494.2 million, a 96.35% increase from a year earlier, with the FY2025 full-year figure at $71.1 million, up 3.21% from the prior year.
• Liabilities and Shareholders Equity improved to $253.2 million in Q1 2026 per CRVS's latest filing, from $71.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $253.2 million in Q1 2026 and bottomed at $40.1 million in Q1 2024.
• The 5-year median for Liabilities and Shareholders Equity is $68.2 million (2022), against an average of $79.0 million.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 42.54% in 2023 and soared 325.98% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $68.2 million in 2022, then slumped by 33.25% to $45.6 million in 2023, then surged by 51.27% to $68.9 million in 2024, then grew by 3.21% to $71.1 million in 2025, then jumped by 256.02% to $253.2 million in 2026.
• Per Business Quant, the three latest CRVS Liabilities and Shareholders Equity figures stand at $253.2 million (Q1 2026), $71.1 million (Q4 2025), and $80.5 million (Q3 2025).